5 years ago

Phase 1 clinical trial using mbIL21 ex-vivo expanded donor-derived NK cells after haploidentical transplantation.

Ciurea SO, Champlin RE, Schafer JR, Chen J, Denman CJ, Shpall EJ, Gulbis A, Cao K, Lee DA, Ahmed S, Bassett R, Willis D, Rondon G, Rezvani K, Kaur I, Soebbing D
Relapse has emerged as the most important cause of treatment failure after allogeneic hematopoietic stem cell transplantation (HSCT). To test the hypothesis that NK cells can decrease the risk of leukemia relapse we initiated a phase-1 dose-escalation study of expanded donor NK cells infused before and after haploidentical HSCT for high-risk myeloid malignancies. The goals were to determine the safety, feasibility and maximum tolerated dose (MTD). Patients received a melphalan-based reduced-intensity conditioning regimen and post-transplant cyclophosphamide-based GVHD prophylaxis. NK cells were infused on Days -2, +7 and +28 post-transplant. All NK expansions achieved the required cell number, and eleven of thirteen patients enrolled received all three planned NK cell doses (1x105 to 1x108/kg/dose). No infusional reactions or dose-limiting toxicities occurred. All patients engrafted with donor cells. Seven patients (54%) developed grade 1-2 aGVHD, none developed grade 3-4 aGVHD or cGVHD, and a low incidence of viral complications was observed. One patient died of non-relapse mortality and one patient relapsed. All others were alive and in remission at last follow-up (median 14.7 months). NK cell reconstitution was quantitatively, phenotypically, and functionally superior compared to a similar group of patients not receiving NK cells. In conclusion, this trial demonstrated production feasibility and safety of infusing high doses of ex vivo expanded NK cells after haploidentical HSCT without adverse effects, increased GVHD or higher mortality, and was associated with significantly improved NK cell number and function, lower viral infections, and low relapse rate post-transplant.

Publisher URL: https://www.ncbi.nlm.nih.gov/pubmed/28835441

DOI: PubMed:28835441

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.